 Lisa Bero
Concepts (697)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conflict of Interest | 81 | 2023 | 119 | 22.250 |
Why?
| | Drug Industry | 61 | 2023 | 103 | 15.620 |
Why?
| | Research Support as Topic | 39 | 2021 | 108 | 9.170 |
Why?
| | Tobacco Industry | 34 | 2018 | 46 | 7.870 |
Why?
| | Industry | 27 | 2024 | 65 | 6.280 |
Why?
| | Publication Bias | 24 | 2020 | 36 | 6.080 |
Why?
| | Publishing | 34 | 2022 | 124 | 5.960 |
Why?
| | Disclosure | 29 | 2022 | 101 | 5.710 |
Why?
| | Research Design | 32 | 2023 | 928 | 5.700 |
Why?
| | Review Literature as Topic | 23 | 2022 | 61 | 5.360 |
Why?
| | Health Policy | 24 | 2022 | 334 | 5.080 |
Why?
| | Biomedical Research | 25 | 2022 | 585 | 4.980 |
Why?
| | Public Health | 28 | 2023 | 433 | 4.830 |
Why?
| | Evidence-Based Medicine | 26 | 2023 | 668 | 4.660 |
Why?
| | World Health Organization | 23 | 2022 | 102 | 4.630 |
Why?
| | Policy Making | 20 | 2022 | 81 | 4.310 |
Why?
| | Practice Guidelines as Topic | 22 | 2021 | 1394 | 3.990 |
Why?
| | Meta-Analysis as Topic | 17 | 2022 | 158 | 3.650 |
Why?
| | Randomized Controlled Trials as Topic | 24 | 2024 | 1214 | 3.400 |
Why?
| | Bias | 19 | 2024 | 179 | 3.340 |
Why?
| | Scientific Misconduct | 5 | 2022 | 11 | 3.150 |
Why?
| | Pharmaceutical Preparations | 10 | 2022 | 165 | 3.070 |
Why?
| | Mobile Applications | 8 | 2020 | 141 | 3.040 |
Why?
| | Australia | 25 | 2023 | 206 | 2.910 |
Why?
| | Editorial Policies | 10 | 2021 | 45 | 2.690 |
Why?
| | Nutritional Sciences | 6 | 2019 | 37 | 2.640 |
Why?
| | Smoking | 25 | 2016 | 1383 | 2.610 |
Why?
| | Periodicals as Topic | 18 | 2020 | 181 | 2.480 |
Why?
| | Environmental Exposure | 6 | 2021 | 372 | 2.460 |
Why?
| | Humans | 257 | 2024 | 114674 | 2.450 |
Why?
| | Smoking Prevention | 12 | 2012 | 157 | 2.390 |
Why?
| | Health Personnel | 10 | 2021 | 574 | 2.370 |
Why?
| | Food Industry | 6 | 2020 | 14 | 2.250 |
Why?
| | Nutrition Policy | 5 | 2020 | 54 | 2.170 |
Why?
| | Clinical Trials as Topic | 18 | 2021 | 932 | 2.170 |
Why?
| | Observational Studies as Topic | 6 | 2024 | 90 | 2.140 |
Why?
| | Equipment and Supplies | 8 | 2020 | 38 | 2.050 |
Why?
| | Research Report | 5 | 2019 | 75 | 2.050 |
Why?
| | Environmental Health | 7 | 2019 | 30 | 2.010 |
Why?
| | Information Dissemination | 10 | 2021 | 186 | 1.970 |
Why?
| | Guideline Adherence | 8 | 2019 | 490 | 1.900 |
Why?
| | United States Food and Drug Administration | 14 | 2015 | 172 | 1.880 |
Why?
| | Marketing | 9 | 2021 | 24 | 1.840 |
Why?
| | Tobacco Smoke Pollution | 16 | 2006 | 217 | 1.750 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2018 | 373 | 1.740 |
Why?
| | Ethics, Research | 5 | 2020 | 34 | 1.660 |
Why?
| | Environmental Pollutants | 6 | 2018 | 110 | 1.650 |
Why?
| | Government Regulation | 12 | 2019 | 46 | 1.570 |
Why?
| | Drugs, Essential | 5 | 2018 | 6 | 1.560 |
Why?
| | Propaganda | 3 | 2019 | 3 | 1.540 |
Why?
| | Public Policy | 7 | 2016 | 61 | 1.530 |
Why?
| | Research | 18 | 2020 | 394 | 1.520 |
Why?
| | Politics | 8 | 2020 | 79 | 1.420 |
Why?
| | United States | 65 | 2023 | 12182 | 1.400 |
Why?
| | Peer Review, Research | 9 | 2015 | 34 | 1.390 |
Why?
| | Data Collection | 9 | 2019 | 620 | 1.390 |
Why?
| | Qualitative Research | 13 | 2023 | 936 | 1.360 |
Why?
| | Cross-Sectional Studies | 28 | 2023 | 4408 | 1.340 |
Why?
| | Evidence-Based Practice | 4 | 2020 | 185 | 1.300 |
Why?
| | Physicians | 12 | 2023 | 772 | 1.290 |
Why?
| | Authorship | 10 | 2020 | 31 | 1.290 |
Why?
| | Nutritional Status | 5 | 2020 | 287 | 1.270 |
Why?
| | Guidelines as Topic | 7 | 2020 | 243 | 1.260 |
Why?
| | Coronavirus Infections | 4 | 2021 | 330 | 1.260 |
Why?
| | Delivery of Health Care | 5 | 2024 | 833 | 1.230 |
Why?
| | Bibliometrics | 5 | 2018 | 44 | 1.190 |
Why?
| | Pharmacy and Therapeutics Committee | 2 | 2020 | 2 | 1.160 |
Why?
| | Commerce | 8 | 2020 | 61 | 1.150 |
Why?
| | Vitamin D | 2 | 2021 | 341 | 1.130 |
Why?
| | Policy | 4 | 2022 | 137 | 1.120 |
Why?
| | Community Pharmacy Services | 2 | 2022 | 42 | 1.110 |
Why?
| | Interprofessional Relations | 5 | 2021 | 249 | 1.090 |
Why?
| | Research Personnel | 4 | 2017 | 149 | 1.090 |
Why?
| | Cardiovascular Diseases | 7 | 2021 | 1727 | 1.080 |
Why?
| | Risk Management | 2 | 2022 | 89 | 1.070 |
Why?
| | Health Promotion | 8 | 2019 | 686 | 1.060 |
Why?
| | Occupational Health | 5 | 2019 | 165 | 1.050 |
Why?
| | Drug Approval | 5 | 2015 | 78 | 1.050 |
Why?
| | Education, Medical, Continuing | 4 | 2019 | 117 | 1.040 |
Why?
| | Bone and Bones | 2 | 2021 | 278 | 1.020 |
Why?
| | Deprescriptions | 5 | 2023 | 27 | 0.990 |
Why?
| | Practice Patterns, Physicians' | 12 | 2021 | 1177 | 0.980 |
Why?
| | Lobbying | 6 | 2006 | 8 | 0.970 |
Why?
| | Diet | 5 | 2020 | 1080 | 0.970 |
Why?
| | Interrupted Time Series Analysis | 7 | 2022 | 44 | 0.960 |
Why?
| | Risk Assessment | 10 | 2022 | 2968 | 0.930 |
Why?
| | Toxicity Tests | 3 | 2016 | 28 | 0.910 |
Why?
| | Financial Support | 5 | 2019 | 18 | 0.910 |
Why?
| | Medical Overuse | 4 | 2019 | 31 | 0.910 |
Why?
| | Spinal Cord Stimulation | 1 | 2024 | 7 | 0.900 |
Why?
| | Workplace | 4 | 2009 | 220 | 0.900 |
Why?
| | Telemedicine | 4 | 2019 | 662 | 0.880 |
Why?
| | Pandemics | 7 | 2023 | 1317 | 0.870 |
Why?
| | Consumer Advocacy | 2 | 2020 | 12 | 0.870 |
Why?
| | Advanced Practice Nursing | 1 | 2023 | 22 | 0.870 |
Why?
| | Formularies as Topic | 3 | 2018 | 6 | 0.860 |
Why?
| | Codeine | 1 | 2022 | 7 | 0.840 |
Why?
| | Dietary Supplements | 2 | 2021 | 460 | 0.830 |
Why?
| | Health Education | 2 | 2018 | 323 | 0.810 |
Why?
| | Health Priorities | 2 | 2012 | 34 | 0.800 |
Why?
| | Nursing Care | 1 | 2022 | 31 | 0.800 |
Why?
| | Epidemiologic Methods | 2 | 2022 | 72 | 0.800 |
Why?
| | Drug Evaluation | 5 | 2012 | 77 | 0.800 |
Why?
| | Decision Making | 9 | 2014 | 782 | 0.790 |
Why?
| | Confidentiality | 2 | 2021 | 67 | 0.780 |
Why?
| | Tobacco Products | 4 | 2018 | 98 | 0.780 |
Why?
| | Retraction of Publication as Topic | 1 | 2021 | 1 | 0.760 |
Why?
| | Recommended Dietary Allowances | 1 | 2021 | 18 | 0.750 |
Why?
| | Interviews as Topic | 7 | 2019 | 583 | 0.740 |
Why?
| | Group Practice | 1 | 2021 | 7 | 0.740 |
Why?
| | Attitude | 4 | 2013 | 229 | 0.740 |
Why?
| | Advisory Committees | 6 | 2020 | 208 | 0.740 |
Why?
| | Bone Remodeling | 1 | 2021 | 65 | 0.730 |
Why?
| | Atherosclerosis | 2 | 2015 | 341 | 0.720 |
Why?
| | Technology Transfer | 2 | 2019 | 13 | 0.720 |
Why?
| | Contact Tracing | 1 | 2020 | 16 | 0.720 |
Why?
| | Calcium | 2 | 2021 | 1108 | 0.710 |
Why?
| | Gift Giving | 2 | 2019 | 9 | 0.700 |
Why?
| | Checklist | 1 | 2021 | 83 | 0.700 |
Why?
| | Betacoronavirus | 2 | 2020 | 250 | 0.700 |
Why?
| | Science | 3 | 2007 | 48 | 0.690 |
Why?
| | Societies, Scientific | 1 | 2020 | 47 | 0.690 |
Why?
| | Societies | 1 | 2020 | 38 | 0.690 |
Why?
| | Organizational Policy | 7 | 2011 | 68 | 0.690 |
Why?
| | Beverages | 2 | 2019 | 60 | 0.690 |
Why?
| | Databases, Factual | 5 | 2020 | 1125 | 0.680 |
Why?
| | Attitude to Health | 6 | 2015 | 406 | 0.670 |
Why?
| | Marketing of Health Services | 3 | 2018 | 12 | 0.670 |
Why?
| | Dental Research | 1 | 2019 | 8 | 0.660 |
Why?
| | Calcium, Dietary | 1 | 2019 | 55 | 0.660 |
Why?
| | Whole Grains | 1 | 2019 | 3 | 0.660 |
Why?
| | Patient Advocacy | 2 | 2019 | 66 | 0.660 |
Why?
| | Off-Label Use | 3 | 2015 | 51 | 0.660 |
Why?
| | Pharmacists | 7 | 2022 | 233 | 0.650 |
Why?
| | Selection Bias | 2 | 2017 | 33 | 0.640 |
Why?
| | Analgesics, Opioid | 7 | 2023 | 771 | 0.640 |
Why?
| | Gynecology | 1 | 2021 | 163 | 0.640 |
Why?
| | Hazardous Substances | 2 | 2018 | 9 | 0.630 |
Why?
| | Tobacco Use Disorder | 4 | 2010 | 234 | 0.630 |
Why?
| | Internet | 4 | 2019 | 596 | 0.630 |
Why?
| | Public Opinion | 6 | 2015 | 59 | 0.630 |
Why?
| | Developing Countries | 4 | 2018 | 235 | 0.630 |
Why?
| | International Cooperation | 7 | 2011 | 171 | 0.620 |
Why?
| | Journalism | 2 | 2012 | 5 | 0.620 |
Why?
| | Professional Role | 4 | 2022 | 149 | 0.620 |
Why?
| | Cooperative Behavior | 3 | 2013 | 381 | 0.620 |
Why?
| | Vitamins | 1 | 2019 | 151 | 0.620 |
Why?
| | Nicotine | 8 | 2006 | 265 | 0.610 |
Why?
| | Health Behavior | 4 | 2021 | 704 | 0.610 |
Why?
| | Fluorocarbons | 2 | 2023 | 94 | 0.610 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 338 | 0.610 |
Why?
| | Quality Control | 8 | 2013 | 144 | 0.610 |
Why?
| | Food Analysis | 1 | 2018 | 18 | 0.600 |
Why?
| | Writing | 2 | 2019 | 82 | 0.600 |
Why?
| | Access to Information | 3 | 2014 | 47 | 0.600 |
Why?
| | Pharmaceutical Services | 3 | 2013 | 77 | 0.600 |
Why?
| | Health Services | 3 | 2013 | 103 | 0.590 |
Why?
| | Capital Financing | 1 | 2017 | 5 | 0.590 |
Why?
| | Databases, Bibliographic | 3 | 2014 | 29 | 0.590 |
Why?
| | Disease Outbreaks | 1 | 2020 | 307 | 0.580 |
Why?
| | Nurses | 2 | 2016 | 145 | 0.580 |
Why?
| | Population Health | 1 | 2018 | 42 | 0.580 |
Why?
| | Cannabis | 1 | 2023 | 384 | 0.570 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 413 | 0.560 |
Why?
| | Vaccines | 1 | 2022 | 375 | 0.560 |
Why?
| | Interinstitutional Relations | 5 | 2013 | 54 | 0.550 |
Why?
| | Peer Review | 5 | 2015 | 43 | 0.550 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2015 | 161 | 0.550 |
Why?
| | Government Agencies | 2 | 2015 | 15 | 0.540 |
Why?
| | Primary Prevention | 1 | 2018 | 172 | 0.540 |
Why?
| | Tobacco Use Cessation | 1 | 2016 | 21 | 0.540 |
Why?
| | Sweetening Agents | 1 | 2016 | 37 | 0.530 |
Why?
| | Drug Prescriptions | 4 | 2022 | 239 | 0.530 |
Why?
| | California | 9 | 2013 | 353 | 0.520 |
Why?
| | Atrazine | 1 | 2015 | 8 | 0.520 |
Why?
| | Drug Overdose | 1 | 2020 | 292 | 0.510 |
Why?
| | Libraries, Digital | 2 | 2012 | 4 | 0.510 |
Why?
| | Medicaid | 4 | 2013 | 407 | 0.510 |
Why?
| | Cohort Studies | 7 | 2022 | 4895 | 0.500 |
Why?
| | Pharmacies | 1 | 2015 | 32 | 0.500 |
Why?
| | Fetal Development | 2 | 2016 | 246 | 0.500 |
Why?
| | Patient Care Planning | 1 | 2016 | 139 | 0.500 |
Why?
| | Databases, Pharmaceutical | 1 | 2015 | 5 | 0.500 |
Why?
| | Obesity | 3 | 2017 | 2508 | 0.490 |
Why?
| | Anticoagulants | 1 | 2019 | 550 | 0.490 |
Why?
| | Epidemiologic Studies | 2 | 2022 | 57 | 0.490 |
Why?
| | Models, Organizational | 2 | 2008 | 140 | 0.490 |
Why?
| | Fees, Pharmaceutical | 2 | 2014 | 13 | 0.490 |
Why?
| | Academic Medical Centers | 4 | 2018 | 411 | 0.490 |
Why?
| | Information Services | 4 | 2002 | 44 | 0.480 |
Why?
| | Medication Adherence | 1 | 2019 | 536 | 0.480 |
Why?
| | Air Pollution, Indoor | 2 | 2009 | 108 | 0.480 |
Why?
| | Canada | 7 | 2022 | 322 | 0.480 |
Why?
| | Caprylates | 1 | 2014 | 19 | 0.470 |
Why?
| | Knowledge | 2 | 2012 | 49 | 0.470 |
Why?
| | Treatment Outcome | 15 | 2018 | 9088 | 0.470 |
Why?
| | Quality of Health Care | 4 | 2012 | 573 | 0.470 |
Why?
| | Occupational Exposure | 3 | 2022 | 255 | 0.460 |
Why?
| | Expert Testimony | 3 | 2020 | 36 | 0.460 |
Why?
| | Teaching Materials | 2 | 2007 | 25 | 0.460 |
Why?
| | Universities | 4 | 2007 | 340 | 0.450 |
Why?
| | Social Support | 1 | 2017 | 528 | 0.450 |
Why?
| | Depressive Disorder, Major | 1 | 2017 | 301 | 0.450 |
Why?
| | Counseling | 1 | 2016 | 342 | 0.450 |
Why?
| | Substance-Related Disorders | 7 | 2016 | 947 | 0.440 |
Why?
| | Community Participation | 2 | 2010 | 116 | 0.440 |
Why?
| | Ambulatory Care | 3 | 2010 | 478 | 0.430 |
Why?
| | Mass Media | 5 | 2001 | 37 | 0.430 |
Why?
| | Cyclohexanecarboxylic Acids | 3 | 2009 | 22 | 0.430 |
Why?
| | Amines | 3 | 2009 | 34 | 0.430 |
Why?
| | Financial Management | 3 | 2012 | 15 | 0.420 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 307 | 0.420 |
Why?
| | Overweight | 1 | 2016 | 471 | 0.420 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 214 | 0.410 |
Why?
| | Macular Degeneration | 1 | 2014 | 152 | 0.410 |
Why?
| | Carcinogens | 2 | 2020 | 103 | 0.410 |
Why?
| | Attitude of Health Personnel | 7 | 2023 | 975 | 0.410 |
Why?
| | Thinking | 1 | 2013 | 53 | 0.410 |
Why?
| | Health Services Accessibility | 4 | 2015 | 763 | 0.400 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2009 | 144 | 0.400 |
Why?
| | Body Weight | 1 | 2016 | 869 | 0.400 |
Why?
| | Global Health | 3 | 2020 | 287 | 0.400 |
Why?
| | Medication Therapy Management | 1 | 2013 | 67 | 0.390 |
Why?
| | Device Approval | 4 | 2015 | 21 | 0.390 |
Why?
| | Federal Government | 3 | 2009 | 26 | 0.390 |
Why?
| | Birth Weight | 1 | 2014 | 440 | 0.380 |
Why?
| | Human Experimentation | 2 | 2009 | 12 | 0.380 |
Why?
| | Publications | 3 | 2020 | 37 | 0.380 |
Why?
| | Oncologists | 2 | 2021 | 31 | 0.370 |
Why?
| | Thrombosis | 1 | 2014 | 298 | 0.370 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2021 | 1183 | 0.370 |
Why?
| | Prejudice | 3 | 2017 | 55 | 0.370 |
Why?
| | Organizations, Nonprofit | 1 | 2011 | 17 | 0.370 |
Why?
| | Decision Support Techniques | 1 | 2014 | 355 | 0.370 |
Why?
| | Patient Education as Topic | 2 | 2013 | 680 | 0.360 |
Why?
| | Teaching | 1 | 2013 | 213 | 0.360 |
Why?
| | Decision Making, Organizational | 2 | 2007 | 22 | 0.360 |
Why?
| | Relief Work | 1 | 2010 | 20 | 0.360 |
Why?
| | Public Relations | 5 | 2017 | 6 | 0.350 |
Why?
| | Child Welfare | 1 | 2012 | 192 | 0.350 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 663 | 0.340 |
Why?
| | Women's Health | 1 | 2012 | 271 | 0.340 |
Why?
| | Congresses as Topic | 4 | 1997 | 195 | 0.340 |
Why?
| | Drug Labeling | 2 | 2013 | 42 | 0.340 |
Why?
| | Cluster Analysis | 1 | 2011 | 455 | 0.340 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2014 | 238 | 0.340 |
Why?
| | Health Care Sector | 2 | 2020 | 24 | 0.340 |
Why?
| | Prescription Drugs | 4 | 2017 | 116 | 0.330 |
Why?
| | Occupational Diseases | 2 | 2022 | 128 | 0.330 |
Why?
| | Health Care Costs | 4 | 2019 | 381 | 0.320 |
Why?
| | Economic Development | 1 | 2009 | 3 | 0.320 |
Why?
| | Poverty | 2 | 2010 | 442 | 0.320 |
Why?
| | Ethics, Institutional | 1 | 2009 | 4 | 0.320 |
Why?
| | Social Control Policies | 1 | 2008 | 1 | 0.320 |
Why?
| | Ethics, Professional | 1 | 2009 | 14 | 0.320 |
Why?
| | Life Style | 2 | 2021 | 430 | 0.320 |
Why?
| | Restaurants | 1 | 2008 | 16 | 0.320 |
Why?
| | Neoplasms | 8 | 2023 | 2097 | 0.320 |
Why?
| | Law Enforcement | 1 | 2008 | 37 | 0.310 |
Why?
| | Thiazolidinediones | 1 | 2009 | 142 | 0.300 |
Why?
| | Morals | 1 | 2009 | 65 | 0.300 |
Why?
| | Laboratories | 1 | 2009 | 95 | 0.300 |
Why?
| | Trust | 2 | 2019 | 105 | 0.290 |
Why?
| | Uncertainty | 2 | 2021 | 95 | 0.290 |
Why?
| | Ethics Committees, Research | 1 | 2007 | 38 | 0.290 |
Why?
| | Privacy | 3 | 2020 | 28 | 0.290 |
Why?
| | Research Subjects | 1 | 2007 | 40 | 0.290 |
Why?
| | Minority Groups | 1 | 2009 | 227 | 0.280 |
Why?
| | Drug and Narcotic Control | 3 | 2021 | 29 | 0.280 |
Why?
| | Consumer Organizations | 1 | 2007 | 1 | 0.280 |
Why?
| | Smoking Cessation | 5 | 2018 | 374 | 0.280 |
Why?
| | Osteoporosis | 3 | 2021 | 226 | 0.280 |
Why?
| | Plants, Toxic | 6 | 1995 | 22 | 0.280 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2017 | 47 | 0.280 |
Why?
| | Deception | 1 | 2007 | 16 | 0.280 |
Why?
| | Europe | 4 | 2021 | 334 | 0.280 |
Why?
| | Health Status Disparities | 1 | 2009 | 200 | 0.280 |
Why?
| | Books | 1 | 2006 | 3 | 0.270 |
Why?
| | Aerospace Medicine | 1 | 2006 | 19 | 0.270 |
Why?
| | Aircraft | 1 | 2006 | 26 | 0.270 |
Why?
| | United States Dept. of Health and Human Services | 1 | 2006 | 2 | 0.260 |
Why?
| | Adolescent Behavior | 2 | 2002 | 489 | 0.260 |
Why?
| | Nonprescription Drugs | 1 | 2006 | 68 | 0.250 |
Why?
| | Disease | 2 | 2019 | 85 | 0.250 |
Why?
| | Consumer Product Safety | 3 | 2019 | 30 | 0.250 |
Why?
| | Insurance Claim Reporting | 1 | 2005 | 22 | 0.250 |
Why?
| | MEDLINE | 3 | 2014 | 22 | 0.250 |
Why?
| | Documentation | 4 | 2018 | 167 | 0.250 |
Why?
| | Animals | 19 | 2020 | 31706 | 0.250 |
Why?
| | Bone Density | 1 | 2009 | 432 | 0.250 |
Why?
| | Female | 23 | 2023 | 59499 | 0.250 |
Why?
| | Drug Utilization | 3 | 2022 | 167 | 0.240 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 321 | 0.240 |
Why?
| | Harm Reduction | 1 | 2004 | 24 | 0.240 |
Why?
| | Case-Control Studies | 2 | 2024 | 3003 | 0.240 |
Why?
| | International Classification of Diseases | 1 | 2005 | 116 | 0.230 |
Why?
| | Antihypertensive Agents | 1 | 2007 | 429 | 0.230 |
Why?
| | Cost-Benefit Analysis | 4 | 2015 | 544 | 0.230 |
Why?
| | Evaluation Studies as Topic | 3 | 2019 | 167 | 0.220 |
Why?
| | Data Accuracy | 2 | 2021 | 48 | 0.220 |
Why?
| | Receptors, Opioid | 3 | 1988 | 19 | 0.220 |
Why?
| | Male | 19 | 2023 | 55589 | 0.220 |
Why?
| | Consultants | 2 | 2020 | 13 | 0.220 |
Why?
| | Quarantine | 2 | 2020 | 24 | 0.220 |
Why?
| | Data Mining | 2 | 2015 | 100 | 0.220 |
Why?
| | Schizophrenia | 1 | 2007 | 414 | 0.220 |
Why?
| | Sample Size | 2 | 2014 | 112 | 0.220 |
Why?
| | Mental Health | 2 | 2019 | 562 | 0.210 |
Why?
| | Journal Impact Factor | 3 | 2020 | 27 | 0.210 |
Why?
| | Prolactin | 4 | 1987 | 96 | 0.210 |
Why?
| | Drug Therapy | 5 | 2011 | 76 | 0.210 |
Why?
| | State Government | 3 | 2009 | 41 | 0.210 |
Why?
| | Estonia | 2 | 2012 | 2 | 0.210 |
Why?
| | Alcohol Drinking | 1 | 2008 | 651 | 0.210 |
Why?
| | Private Sector | 2 | 2000 | 51 | 0.210 |
Why?
| | Health Status | 2 | 2021 | 722 | 0.210 |
Why?
| | Datasets as Topic | 2 | 2020 | 99 | 0.210 |
Why?
| | Program Development | 2 | 2016 | 341 | 0.200 |
Why?
| | Risk | 2 | 2016 | 812 | 0.200 |
Why?
| | Fraud | 1 | 2022 | 8 | 0.200 |
Why?
| | Risk Factors | 7 | 2022 | 8632 | 0.200 |
Why?
| | Child | 9 | 2020 | 18412 | 0.200 |
Why?
| | Artificial Intelligence | 1 | 2023 | 144 | 0.200 |
Why?
| | Libraries, Medical | 1 | 2002 | 9 | 0.200 |
Why?
| | Analgesics | 1 | 2023 | 158 | 0.200 |
Why?
| | Torsades de Pointes | 1 | 2022 | 17 | 0.200 |
Why?
| | Newspapers as Topic | 2 | 2001 | 9 | 0.200 |
Why?
| | Truth Disclosure | 7 | 2011 | 39 | 0.200 |
Why?
| | Program Evaluation | 4 | 2020 | 822 | 0.190 |
Why?
| | History, 21st Century | 2 | 2018 | 159 | 0.190 |
Why?
| | Chemical Industry | 2 | 2013 | 9 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2018 | 1660 | 0.190 |
Why?
| | Healthcare Disparities | 2 | 2021 | 480 | 0.190 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.190 |
Why?
| | Long QT Syndrome | 1 | 2022 | 59 | 0.190 |
Why?
| | Facility Regulation and Control | 1 | 2000 | 2 | 0.180 |
Why?
| | Sodium, Dietary | 1 | 2021 | 36 | 0.180 |
Why?
| | Adult | 9 | 2023 | 30546 | 0.180 |
Why?
| | Infant Formula | 1 | 2021 | 74 | 0.180 |
Why?
| | Faculty, Medical | 2 | 2000 | 228 | 0.180 |
Why?
| | Health Care Surveys | 2 | 2013 | 539 | 0.180 |
Why?
| | Administrative Personnel | 1 | 2020 | 29 | 0.180 |
Why?
| | Sierra Leone | 1 | 2020 | 2 | 0.180 |
Why?
| | Botswana | 1 | 2020 | 7 | 0.180 |
Why?
| | United States Agency for Healthcare Research and Quality | 1 | 2020 | 9 | 0.180 |
Why?
| | Patient Isolation | 1 | 2020 | 18 | 0.180 |
Why?
| | Thiadiazines | 1 | 2020 | 2 | 0.170 |
Why?
| | Codes of Ethics | 2 | 2018 | 16 | 0.170 |
Why?
| | Whooping Cough | 1 | 2020 | 49 | 0.170 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2020 | 33 | 0.170 |
Why?
| | Organizational Case Studies | 3 | 2010 | 69 | 0.170 |
Why?
| | Medicare | 1 | 2005 | 665 | 0.170 |
Why?
| | Reproduction | 1 | 2021 | 178 | 0.170 |
Why?
| | Psychology, Adolescent | 1 | 2000 | 63 | 0.170 |
Why?
| | Food Safety | 1 | 2020 | 16 | 0.170 |
Why?
| | Chronic Pain | 1 | 2023 | 210 | 0.170 |
Why?
| | Postpartum Hemorrhage | 1 | 2019 | 14 | 0.170 |
Why?
| | Dabigatran | 1 | 2019 | 22 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2022 | 12549 | 0.160 |
Why?
| | Social Control, Formal | 1 | 2019 | 11 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 30 | 0.160 |
Why?
| | Food Supply | 1 | 2020 | 64 | 0.160 |
Why?
| | Models, Theoretical | 2 | 2020 | 515 | 0.160 |
Why?
| | Organizational Affiliation | 2 | 2000 | 8 | 0.160 |
Why?
| | Computer Security | 1 | 2019 | 18 | 0.160 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1879 | 0.160 |
Why?
| | Secondary Prevention | 1 | 2020 | 222 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2019 | 73 | 0.160 |
Why?
| | Schools | 1 | 2002 | 399 | 0.160 |
Why?
| | Middle Aged | 5 | 2023 | 26735 | 0.150 |
Why?
| | Pyridones | 1 | 2019 | 123 | 0.150 |
Why?
| | Health Risk Behaviors | 1 | 2018 | 13 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 56 | 0.150 |
Why?
| | Information Storage and Retrieval | 2 | 2015 | 106 | 0.150 |
Why?
| | Morphine | 4 | 1987 | 121 | 0.150 |
Why?
| | Eating | 1 | 2020 | 344 | 0.150 |
Why?
| | Professional Practice | 1 | 1998 | 62 | 0.150 |
Why?
| | Patient Satisfaction | 2 | 2017 | 578 | 0.150 |
Why?
| | Practice Management, Medical | 1 | 2018 | 34 | 0.150 |
Why?
| | Oral Health | 1 | 2020 | 140 | 0.150 |
Why?
| | Food | 1 | 2019 | 160 | 0.150 |
Why?
| | Statistics as Topic | 1 | 2019 | 292 | 0.150 |
Why?
| | United Kingdom | 3 | 2022 | 226 | 0.150 |
Why?
| | Urinary Bladder, Overactive | 1 | 2018 | 20 | 0.150 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 196 | 0.150 |
Why?
| | Rivaroxaban | 1 | 2019 | 211 | 0.150 |
Why?
| | Tuberculosis | 1 | 2020 | 241 | 0.140 |
Why?
| | Leadership | 1 | 2020 | 292 | 0.140 |
Why?
| | Linear Models | 2 | 2020 | 768 | 0.140 |
Why?
| | Health Resources | 1 | 2018 | 122 | 0.140 |
Why?
| | Pregnancy | 6 | 2019 | 5518 | 0.140 |
Why?
| | Environmental Monitoring | 1 | 2018 | 254 | 0.140 |
Why?
| | Patient Participation | 2 | 1997 | 359 | 0.140 |
Why?
| | Food Handling | 1 | 2016 | 49 | 0.140 |
Why?
| | Patient Selection | 2 | 2011 | 641 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2016 | 75 | 0.130 |
Why?
| | Triclosan | 1 | 2016 | 9 | 0.130 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 385 | 0.130 |
Why?
| | Pyrazoles | 1 | 2019 | 362 | 0.130 |
Why?
| | Brain Chemistry | 2 | 1988 | 115 | 0.130 |
Why?
| | Primary Health Care | 2 | 2020 | 1513 | 0.130 |
Why?
| | Judgment | 1 | 2016 | 55 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 231 | 0.130 |
Why?
| | Information Centers | 1 | 1995 | 4 | 0.130 |
Why?
| | Endocrine Disruptors | 1 | 2016 | 34 | 0.130 |
Why?
| | Thyroxine | 1 | 2016 | 56 | 0.130 |
Why?
| | Epidemiologic Research Design | 1 | 2016 | 27 | 0.130 |
Why?
| | Malnutrition | 1 | 2016 | 62 | 0.130 |
Why?
| | Infant, Newborn | 2 | 2020 | 5045 | 0.130 |
Why?
| | 5-Hydroxytryptophan | 2 | 1987 | 22 | 0.130 |
Why?
| | Sex Factors | 2 | 2012 | 1715 | 0.130 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 4622 | 0.130 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 114 | 0.130 |
Why?
| | Hypertension | 2 | 2010 | 1056 | 0.120 |
Why?
| | Depression | 1 | 2003 | 1134 | 0.120 |
Why?
| | Health | 1 | 2015 | 74 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2018 | 332 | 0.120 |
Why?
| | Ranibizumab | 1 | 2014 | 18 | 0.120 |
Why?
| | Medical Informatics | 1 | 2015 | 90 | 0.120 |
Why?
| | Italy | 1 | 2014 | 92 | 0.120 |
Why?
| | Nursing Staff, Hospital | 1 | 2016 | 122 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2011 | 68 | 0.120 |
Why?
| | Bevacizumab | 1 | 2014 | 115 | 0.110 |
Why?
| | Legislation, Food | 1 | 2013 | 2 | 0.110 |
Why?
| | Vaccination | 1 | 2022 | 1204 | 0.110 |
Why?
| | Food Additives | 1 | 2013 | 7 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2005 | 2177 | 0.110 |
Why?
| | History, 20th Century | 2 | 2007 | 264 | 0.110 |
Why?
| | Equipment Safety | 2 | 2010 | 39 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1121 | 0.110 |
Why?
| | Nursing Homes | 1 | 2015 | 138 | 0.110 |
Why?
| | Search Engine | 1 | 2013 | 9 | 0.110 |
Why?
| | Physician's Role | 1 | 2015 | 197 | 0.110 |
Why?
| | Health Services Research | 1 | 1996 | 371 | 0.110 |
Why?
| | Clinical Protocols | 2 | 2009 | 233 | 0.110 |
Why?
| | Antipsychotic Agents | 1 | 2015 | 184 | 0.100 |
Why?
| | Health Planning Guidelines | 1 | 2012 | 25 | 0.100 |
Why?
| | Reimbursement Mechanisms | 1 | 2013 | 77 | 0.100 |
Why?
| | Total Quality Management | 1 | 2012 | 61 | 0.100 |
Why?
| | Random Allocation | 1 | 2013 | 335 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2019 | 749 | 0.100 |
Why?
| | Gastroenterology | 1 | 2014 | 159 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 900 | 0.100 |
Why?
| | Pain | 3 | 2023 | 705 | 0.100 |
Why?
| | Legislation, Drug | 2 | 2010 | 78 | 0.100 |
Why?
| | Switzerland | 1 | 2011 | 17 | 0.100 |
Why?
| | Americas | 1 | 2011 | 19 | 0.100 |
Why?
| | Comprehension | 1 | 2013 | 156 | 0.100 |
Why?
| | Mammography | 1 | 2012 | 105 | 0.090 |
Why?
| | Libraries | 1 | 2011 | 3 | 0.090 |
Why?
| | Guatemala | 1 | 2012 | 266 | 0.090 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2011 | 10 | 0.090 |
Why?
| | Health Services Needs and Demand | 1 | 2013 | 243 | 0.090 |
Why?
| | Prevalence | 3 | 2022 | 2251 | 0.090 |
Why?
| | Self Concept | 1 | 2012 | 214 | 0.090 |
Why?
| | Eclampsia | 1 | 2010 | 4 | 0.090 |
Why?
| | Tocolytic Agents | 1 | 2010 | 15 | 0.090 |
Why?
| | Time Factors | 1 | 2021 | 6115 | 0.090 |
Why?
| | Magnesium Sulfate | 1 | 2010 | 16 | 0.090 |
Why?
| | Serotonin | 3 | 1987 | 292 | 0.090 |
Why?
| | Educational Status | 1 | 2012 | 412 | 0.090 |
Why?
| | Age Factors | 2 | 2012 | 2894 | 0.090 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 311 | 0.090 |
Why?
| | Mental Disorders | 1 | 2018 | 892 | 0.090 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2010 | 3 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 249 | 0.090 |
Why?
| | Health Surveys | 1 | 2012 | 443 | 0.090 |
Why?
| | Informed Consent | 1 | 2011 | 161 | 0.090 |
Why?
| | Health Facilities | 1 | 2010 | 72 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1842 | 0.090 |
Why?
| | Rats, Inbred Strains | 5 | 1988 | 362 | 0.090 |
Why?
| | Radiology | 1 | 2012 | 141 | 0.080 |
Why?
| | Mandatory Programs | 1 | 2009 | 15 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2016 | 2763 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.080 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 485 | 0.080 |
Why?
| | Disasters | 1 | 2010 | 88 | 0.080 |
Why?
| | Growth Hormone | 2 | 1987 | 103 | 0.080 |
Why?
| | Vinyl Chloride | 1 | 2009 | 2 | 0.080 |
Why?
| | Multivariate Analysis | 2 | 2006 | 1430 | 0.080 |
Why?
| | Lead Poisoning | 1 | 2009 | 17 | 0.080 |
Why?
| | Learning | 1 | 2012 | 350 | 0.080 |
Why?
| | Rats | 8 | 2016 | 4958 | 0.080 |
Why?
| | Financing, Government | 1 | 2009 | 40 | 0.080 |
Why?
| | Placebos | 1 | 2009 | 197 | 0.080 |
Why?
| | Silicosis | 1 | 2009 | 21 | 0.080 |
Why?
| | Pre-Eclampsia | 1 | 2010 | 165 | 0.080 |
Why?
| | Methadone | 2 | 1987 | 77 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1078 | 0.080 |
Why?
| | Smartphone | 2 | 2019 | 73 | 0.080 |
Why?
| | Motivation | 2 | 2020 | 494 | 0.080 |
Why?
| | Coronary Disease | 1 | 2010 | 348 | 0.070 |
Why?
| | Adolescent | 4 | 2010 | 17841 | 0.070 |
Why?
| | Helsinki Declaration | 1 | 2007 | 2 | 0.070 |
Why?
| | Aged | 5 | 2014 | 19073 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2387 | 0.070 |
Why?
| | Logistic Models | 2 | 2006 | 1841 | 0.070 |
Why?
| | Health Plan Implementation | 1 | 2008 | 132 | 0.070 |
Why?
| | Reference Values | 1 | 2009 | 743 | 0.070 |
Why?
| | Financing, Organized | 3 | 2003 | 33 | 0.070 |
Why?
| | Receptors, Dopamine | 1 | 1987 | 12 | 0.070 |
Why?
| | Propylamines | 1 | 1987 | 11 | 0.070 |
Why?
| | Cardiology | 1 | 2009 | 259 | 0.070 |
Why?
| | Persuasive Communication | 1 | 2007 | 12 | 0.070 |
Why?
| | Consumer Behavior | 2 | 2004 | 65 | 0.070 |
Why?
| | Receptors, Serotonin | 1 | 1987 | 32 | 0.070 |
Why?
| | Fluoxetine | 1 | 1987 | 46 | 0.070 |
Why?
| | Culture | 1 | 2007 | 124 | 0.070 |
Why?
| | Regression Analysis | 1 | 2009 | 944 | 0.070 |
Why?
| | Mothers | 1 | 2012 | 651 | 0.070 |
Why?
| | Prospective Studies | 5 | 2020 | 6219 | 0.070 |
Why?
| | Patient Readmission | 1 | 1991 | 610 | 0.070 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1986 | 28 | 0.070 |
Why?
| | Hypothalamus | 1 | 1987 | 147 | 0.070 |
Why?
| | United States Public Health Service | 1 | 2006 | 8 | 0.070 |
Why?
| | Ethics, Medical | 2 | 1999 | 70 | 0.070 |
Why?
| | Catecholamines | 1 | 1986 | 94 | 0.060 |
Why?
| | Geography | 1 | 2006 | 177 | 0.060 |
Why?
| | United States Government Agencies | 1 | 2005 | 6 | 0.060 |
Why?
| | Forms and Records Control | 1 | 2005 | 22 | 0.060 |
Why?
| | Health Maintenance Organizations | 2 | 2003 | 93 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 1004 | 0.060 |
Why?
| | Economic Competition | 1 | 2004 | 13 | 0.060 |
Why?
| | Alkaloids | 1 | 2004 | 22 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2005 | 44 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2011 | 800 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2006 | 179 | 0.060 |
Why?
| | Emergency Service, Hospital | 2 | 2014 | 1815 | 0.060 |
Why?
| | Health Care Coalitions | 1 | 2004 | 8 | 0.060 |
Why?
| | Genetic Engineering | 1 | 2004 | 80 | 0.060 |
Why?
| | Cyproheptadine | 4 | 1987 | 6 | 0.060 |
Why?
| | Odds Ratio | 2 | 2020 | 953 | 0.060 |
Why?
| | Patient Safety | 2 | 2019 | 277 | 0.060 |
Why?
| | Infant | 2 | 2021 | 7961 | 0.060 |
Why?
| | Labor Unions | 1 | 2003 | 3 | 0.050 |
Why?
| | United States Occupational Safety and Health Administration | 1 | 2003 | 8 | 0.050 |
Why?
| | Planning Techniques | 1 | 2003 | 12 | 0.050 |
Why?
| | Liability, Legal | 4 | 1995 | 38 | 0.050 |
Why?
| | Japan | 1 | 2002 | 86 | 0.050 |
Why?
| | Inservice Training | 2 | 2016 | 105 | 0.050 |
Why?
| | Polyvinyls | 1 | 2002 | 17 | 0.050 |
Why?
| | Awareness | 1 | 2003 | 93 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1984 | 470 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2022 | 3 | 0.050 |
Why?
| | Quality of Life | 2 | 2023 | 2353 | 0.050 |
Why?
| | Databases as Topic | 1 | 2002 | 63 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 1988 | 1262 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2002 | 117 | 0.050 |
Why?
| | Polymethacrylic Acids | 1 | 2002 | 61 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 136 | 0.050 |
Why?
| | Pharmacy Service, Hospital | 2 | 1993 | 83 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2012 | 6347 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1013 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 331 | 0.050 |
Why?
| | Feedback | 1 | 2002 | 144 | 0.050 |
Why?
| | Patents as Topic | 1 | 2021 | 1 | 0.050 |
Why?
| | Varenicline | 1 | 2021 | 22 | 0.050 |
Why?
| | Maryland | 1 | 2000 | 37 | 0.050 |
Why?
| | Hand Hygiene | 1 | 2020 | 7 | 0.050 |
Why?
| | Conservation of Natural Resources | 1 | 2002 | 86 | 0.050 |
Why?
| | Perception | 1 | 2003 | 311 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2012 | 1862 | 0.050 |
Why?
| | Radiologists | 1 | 2020 | 35 | 0.040 |
Why?
| | Journalism, Medical | 1 | 2000 | 5 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2000 | 52 | 0.040 |
Why?
| | Computer Graphics | 1 | 2020 | 41 | 0.040 |
Why?
| | Freedom | 1 | 2000 | 12 | 0.040 |
Why?
| | Masks | 1 | 2020 | 46 | 0.040 |
Why?
| | Music | 1 | 2000 | 39 | 0.040 |
Why?
| | Dentistry | 1 | 2020 | 12 | 0.040 |
Why?
| | International Agencies | 1 | 2020 | 30 | 0.040 |
Why?
| | Death | 1 | 2000 | 107 | 0.040 |
Why?
| | Social Values | 1 | 2000 | 36 | 0.040 |
Why?
| | Cost of Illness | 1 | 2022 | 254 | 0.040 |
Why?
| | Social Perception | 1 | 2001 | 95 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 61 | 0.040 |
Why?
| | Insulin | 1 | 2009 | 2079 | 0.040 |
Why?
| | Patient Compliance | 1 | 2003 | 525 | 0.040 |
Why?
| | Ethics | 2 | 1996 | 6 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 560 | 0.040 |
Why?
| | Patient Care Team | 1 | 2003 | 517 | 0.040 |
Why?
| | Employment | 1 | 2020 | 137 | 0.040 |
Why?
| | Foundations | 1 | 2018 | 22 | 0.040 |
Why?
| | Social Behavior | 1 | 2001 | 267 | 0.040 |
Why?
| | Contracts | 1 | 1998 | 9 | 0.040 |
Why?
| | Breast Feeding | 1 | 2021 | 368 | 0.040 |
Why?
| | Fiji | 1 | 2017 | 3 | 0.040 |
Why?
| | Health Status Indicators | 1 | 1998 | 156 | 0.040 |
Why?
| | Consensus | 1 | 2019 | 537 | 0.040 |
Why?
| | Forecasting | 1 | 2018 | 330 | 0.030 |
Why?
| | Technology Assessment, Biomedical | 1 | 1997 | 29 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 9114 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 93 | 0.030 |
Why?
| | Air Pollution | 1 | 2018 | 169 | 0.030 |
Why?
| | Animals, Newborn | 3 | 1987 | 778 | 0.030 |
Why?
| | Capacity Building | 1 | 2016 | 51 | 0.030 |
Why?
| | Software | 1 | 2020 | 530 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 1997 | 93 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 599 | 0.030 |
Why?
| | CD-ROM | 1 | 1995 | 6 | 0.030 |
Why?
| | Medical Informatics Applications | 1 | 1995 | 8 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 40 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2009 | 2096 | 0.030 |
Why?
| | Developed Countries | 1 | 1995 | 28 | 0.030 |
Why?
| | Regional Medical Programs | 1 | 1995 | 4 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1314 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1226 | 0.030 |
Why?
| | Influenza, Human | 1 | 2020 | 546 | 0.030 |
Why?
| | Communication Barriers | 1 | 1996 | 89 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2015 | 30 | 0.030 |
Why?
| | Palliative Care | 1 | 2000 | 644 | 0.030 |
Why?
| | Poison Control Centers | 1 | 1995 | 84 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 1995 | 159 | 0.030 |
Why?
| | Drug Contamination | 1 | 2013 | 52 | 0.030 |
Why?
| | Drug Stability | 1 | 2013 | 151 | 0.030 |
Why?
| | Solubility | 1 | 2013 | 223 | 0.030 |
Why?
| | Family Practice | 1 | 1996 | 427 | 0.030 |
Why?
| | Dementia | 1 | 2015 | 187 | 0.020 |
Why?
| | Precision Medicine | 1 | 2015 | 337 | 0.020 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1991 | 5 | 0.020 |
Why?
| | Referral and Consultation | 2 | 1995 | 634 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 305 | 0.020 |
Why?
| | Dissent and Disputes | 1 | 2011 | 18 | 0.020 |
Why?
| | National Health Programs | 1 | 2010 | 20 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1578 | 0.020 |
Why?
| | Observer Variation | 1 | 1991 | 295 | 0.020 |
Why?
| | Zambia | 1 | 2010 | 69 | 0.020 |
Why?
| | Public Health Practice | 1 | 2010 | 61 | 0.020 |
Why?
| | Training Support | 1 | 2010 | 22 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 1991 | 176 | 0.020 |
Why?
| | Midwifery | 1 | 2010 | 45 | 0.020 |
Why?
| | San Francisco | 3 | 1995 | 54 | 0.020 |
Why?
| | Endpoint Determination | 1 | 2009 | 68 | 0.020 |
Why?
| | beta-Endorphin | 1 | 1988 | 7 | 0.020 |
Why?
| | Obstetrics | 1 | 2010 | 146 | 0.020 |
Why?
| | Aging | 3 | 1987 | 1618 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 328 | 0.020 |
Why?
| | Migraine Disorders | 1 | 2009 | 82 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 331 | 0.020 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1988 | 69 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 1988 | 125 | 0.020 |
Why?
| | Enkephalin, D-Penicillamine (2,5)- | 1 | 1987 | 1 | 0.020 |
Why?
| | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1987 | 3 | 0.020 |
Why?
| | Endorphins | 1 | 1987 | 7 | 0.020 |
Why?
| | Enkephalins | 1 | 1987 | 13 | 0.020 |
Why?
| | Receptors, Opioid, kappa | 1 | 1987 | 11 | 0.020 |
Why?
| | Dynorphins | 1 | 1987 | 9 | 0.020 |
Why?
| | Hydrazines | 1 | 1987 | 28 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 1987 | 52 | 0.020 |
Why?
| | Pyrrolidines | 1 | 1987 | 55 | 0.020 |
Why?
| | Bipolar Disorder | 1 | 2009 | 205 | 0.020 |
Why?
| | p-Chloroamphetamine | 1 | 1987 | 1 | 0.020 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 1987 | 3 | 0.020 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1987 | 19 | 0.020 |
Why?
| | Reserpine | 1 | 1986 | 4 | 0.020 |
Why?
| | Sympatholytics | 1 | 1986 | 13 | 0.020 |
Why?
| | Haloperidol | 1 | 1986 | 35 | 0.020 |
Why?
| | Corticosterone | 1 | 1987 | 211 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1987 | 164 | 0.020 |
Why?
| | Norepinephrine | 1 | 1986 | 201 | 0.020 |
Why?
| | Piperazines | 1 | 1987 | 309 | 0.010 |
Why?
| | Electrochemistry | 1 | 1984 | 79 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 893 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1987 | 666 | 0.010 |
Why?
| | Dopamine | 1 | 1986 | 236 | 0.010 |
Why?
| | Fetus | 1 | 1987 | 700 | 0.010 |
Why?
| | Reading | 1 | 2002 | 149 | 0.010 |
Why?
| | Alendronate | 1 | 2000 | 8 | 0.010 |
Why?
| | Pravastatin | 1 | 2000 | 28 | 0.010 |
Why?
| | Television | 1 | 2000 | 72 | 0.010 |
Why?
| | Outpatients | 2 | 1993 | 326 | 0.010 |
Why?
| | Anticholesteremic Agents | 1 | 2000 | 128 | 0.010 |
Why?
| | Aspirin | 1 | 2000 | 324 | 0.010 |
Why?
| | European Union | 1 | 1997 | 8 | 0.010 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 1995 | 3 | 0.010 |
Why?
| | Fees, Medical | 1 | 1995 | 9 | 0.010 |
Why?
| | Hotlines | 1 | 1995 | 29 | 0.010 |
Why?
| | Physicians' Offices | 1 | 1995 | 16 | 0.010 |
Why?
| | Home Nursing | 1 | 1995 | 26 | 0.010 |
Why?
| | Hospital Charges | 1 | 1995 | 39 | 0.010 |
Why?
| | Propofol | 1 | 1995 | 43 | 0.010 |
Why?
| | Poisoning | 1 | 1995 | 110 | 0.010 |
Why?
| | Insurance, Health | 1 | 1995 | 244 | 0.010 |
Why?
| | Medication Errors | 1 | 1993 | 88 | 0.010 |
Why?
| | Frail Elderly | 1 | 1993 | 106 | 0.010 |
Why?
| | Hospitals, Community | 1 | 1992 | 45 | 0.010 |
Why?
| | Medical Staff, Hospital | 1 | 1992 | 75 | 0.010 |
Why?
| | Curriculum | 1 | 1995 | 819 | 0.010 |
Why?
| | Endocrine Glands | 1 | 1987 | 15 | 0.000 |
Why?
| | Alcoholic Beverages | 1 | 1987 | 17 | 0.000 |
Why?
| | Narcotics | 1 | 1987 | 44 | 0.000 |
Why?
| | Follow-Up Studies | 1 | 1995 | 4411 | 0.000 |
Why?
| | Maternal-Fetal Exchange | 1 | 1987 | 151 | 0.000 |
Why?
| | Cocaine | 1 | 1987 | 153 | 0.000 |
Why?
| | Marijuana Abuse | 1 | 1987 | 212 | 0.000 |
Why?
| | Child Development | 1 | 1987 | 385 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1987 | 3535 | 0.000 |
Why?
|
|
Bero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|